• Concanamycin A: V-ATPase Assay Workflows

  2026-09-18

  Build sharper lysosomal-stress and tumor-cell assays with Concanamycin A, a nanomolar V-type H+-ATPase inhibitor for dissecting acidification, trafficking, apoptosis, and invasion. This workflow connects acute V-ATPase inhibition to the AMPK–SQSTM1/p62–NRF2 stress circuitry highlighted in recent cancer biology research.

• SmD2 Acetylation Links Splicing to PARP Sensitivity

  2026-09-18

  This 2024 Nature Communications study identifies SmD2 acetylation as a regulatory connection between core spliceosome activity, BRCA1/FANC cassette exons, and DNA-damage repair in hepatocellular carcinoma. The work shows that SmD2 depletion or HDAC-inhibitor treatment can increase sensitivity to PARP inhibition, providing a mechanistic rationale for combination treatment in HCC models.

• Abiraterone Acetate in Translational Prostate Cancer

  2026-09-17

  A thought-leadership guide to using Abiraterone acetate as a CYP17 inhibitor in prostate cancer research, with strategic lessons from patient-derived three-dimensional spheroids, model selection, assay design, and translational interpretation.

• MDV3100 in Enzalutamide Resistance Research

  2026-09-17

  MDV3100 enables more than a viability readout: it connects androgen receptor blockade with glycan remodeling, motility, spheroid growth, and therapeutic resistance. This workflow shows how to use Enzalutamide in prostate cancer models while separating acute AR responses from durable metabolic and phenotypic adaptations.

• LY2228820: Practical p38 MAPK Workflow Guide

  2026-09-16

  LY2228820 enables mechanism-focused studies of inflammatory signaling, tumor-cell stress, and angiogenic responses through selective p38α/β inhibition. This workflow guide connects target engagement, phosphatase-aware assay design, combination testing, and troubleshooting for more interpretable preclinical data.

• Lenalidomide (CC-5013): Assay Logic in Myeloma

  2026-09-16

  Explore how Lenalidomide (CC-5013) connects immunomodulation, tumor-cell stress, and innate immune signaling in multiple myeloma research. This evidence-led guide translates recent DOT1L findings into practical assay-design decisions while distinguishing established biology from combination-study hypotheses.

• Oltipraz for Reliable Nrf2 Assays

  2026-09-15

  A scenario-based guide to using Oltipraz (SKU B5958) in cell viability, cytotoxicity, and Nrf2-pathway experiments. It connects solvent control, dose selection, assay interpretation, and MASLD-related ferroptosis research to practical laboratory decisions.

• Machine Learning Prediction of mRNA Vaccine LNPs

  2026-09-15

  The reference study developed a LightGBM model to predict lipid nanoparticle formulations for mRNA vaccines from 325 formulation records, achieving an R² greater than 0.87. Experimental comparison of MC3 and SM-102, together with molecular dynamics modeling, connected computational prediction with biological performance and LNP structural behavior.

• DiscoveryProbe FDA-approved Drug Library Workflow

  2026-09-14

  Turn clinically characterized compounds into a structured workflow for target discovery, phenotypic screening, and drug repositioning screening. The library combines screening-ready DMSO stocks with an iterative assay-to-model strategy that can expose both expected pharmacology and useful off-target biology.

• SmD2 Acetylation and PARP Sensitivity in HCC

  2026-09-14

  The reference study identifies SmD2 as an acetylation-sensitive core spliceosome component that links alternative splicing, DNA-damage repair, and PARP inhibitor response in hepatocellular carcinoma. Its findings support a mechanistic rationale for combining HDAC-directed treatment with PARP inhibition, while also defining important limits for translating the work to other HDAC inhibitors and cancer models.

• Vitamin C Beyond Cancer: Organoid Translation

  2026-09-13

  A translational framework for using Vitamin C ascorbic acid in cancer research while assessing how multilineage organoids can clarify antiviral opportunities, model limitations, and next-step experimental strategy.

• Belinostat Workflow for HDAC Response Assays

  2026-09-12

  Build more informative PXD101 experiments by separating histone deacetylase inhibition, growth arrest, and cell killing. This workflow combines formulation control, orthogonal readouts, and model-specific dose interpretation for bladder and prostate cancer research.

• Saquinavir: A Mechanistic Permeability Guide

  2026-09-11

  Saquinavir is an HIV protease inhibitor whose antiviral mechanism and membrane-partitioning behavior should be evaluated as separate but connected research questions. This guide translates recent IAM-LC and LEKC findings into a practical assay strategy for antiretroviral drug research, HIV infection research, and carefully bounded exploratory applications.

• One-step TUNEL FITC Apoptosis Detection Kit

  2026-09-11

  The One-step TUNEL FITC Apoptosis Detection Kit links DNA fragmentation biology with rigorous tissue and cell assay design. This reference-anchored guide explains how to interpret TUNEL signals in neurotoxicity, cancer research, and mechanistic apoptosis studies.

• Morning Endurance Training and Adaptation in Mice

  2026-09-10

  Hesketh et al. show that endurance training during the early active phase produces faster performance gains than training during the late active phase in female mice, even when the early-training group completes less absolute work. The findings distinguish rapid training adaptation from final glycogen content and point to skeletal-muscle oxidative and contractile remodeling as a more plausible correlate of improved training efficiency.

8539 records 1/570 page Next 12345 下5页 Last page